Ai Therapeutics, Inc.

Lam Therapeutics, Inc.

Yale University

A1 Therapeutics, Inc.

Orphal Therapeutics Inc.

Sean Landrette

Jonathan Marc Rothberg

Henri Lichenstein

Tian Xu

Neil Beeharry

Paul Beckett

Chris Conrad

Sophia Gayle

Peter R Young

Jonathan M Rothberg

Matt Dyer

Marylens Hernandez

Feng Qian

Peter Ronald Young

Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.

Combination therapy with apilimod and glutamatergic agents

The present invention relates to methods for treating cancer with apilimod and related compositions and methods.

Apilimod compositions and methods for using same

The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.

Apilimod compositions and methods for using same in the treatment of renal cancer

The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of 'low dose' HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents.

Methods for treating cancer using HSP90 inhibitors

The present invention relates to methods for treating melanoma with apilimod and related compositions and methods.

Apilimod for use in the treatment of melanoma

The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apillimod and at least one additional anti-viral agent.

Anti-viral compositions containing PIKfyve inhibitors and use thereof

The present disclosure relates to methods for preventing or treating a radiation-induced disease, disorder, or condition by administering apilimod to a subject in need thereof, and related compositions.

Compositions and methods relating to the radioprotective effects of apilimod

The present invention provides compositions and methods of using transposons. In one aspect, methods are disclosed that are useful for identifying negatively selected genes in an insertional mutagenesis screen. In another aspect, compositions for reducing proliferation of a tumor cell expressing an oncogenic RAS include an activator of a WNT pathway. Pharmaceutical compositions for reducing proliferation of tumor cells in a subject in need thereof by administering an effective amount of an activator of a WNT pathway to the tumor cells of the subject are also disclosed.

Growing community of inventors

Meriden, CT, United States of America

Sean Landrette